Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $26.4 million.

  • Tg Therapeutics' Current Deferred Revenue rose 19032.22% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year increase of 19032.22%. This contributed to the annual value of $11.4 million for FY2024, which is 740921.05% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Current Deferred Revenue is $26.4 million, which was up 19032.22% from $23.9 million recorded in Q2 2025.
  • Tg Therapeutics' Current Deferred Revenue's 5-year high stood at $26.4 million during Q3 2025, with a 5-year trough of $152000.0 in Q4 2023.
  • Its 5-year average for Current Deferred Revenue is $5.6 million, with a median of $700000.0 in 2021.
  • Per our database at Business Quant, Tg Therapeutics' Current Deferred Revenue tumbled by 6960.0% in 2023 and then skyrocketed by 740921.05% in 2024.
  • Tg Therapeutics' Current Deferred Revenue (Quarter) stood at $600000.0 in 2021, then fell by 16.67% to $500000.0 in 2022, then tumbled by 69.6% to $152000.0 in 2023, then skyrocketed by 7409.21% to $11.4 million in 2024, then surged by 131.29% to $26.4 million in 2025.
  • Its Current Deferred Revenue was $26.4 million in Q3 2025, compared to $23.9 million in Q2 2025 and $17.1 million in Q1 2025.